Neuropharmacology · 2026
GSDMD-mediated pyroptosis in the dorsal hippocampus is implicated in morphine-induced reward memory in mice.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Dong-Yu, Yang Xi-Xi, Yang Xiao-Yu, Zhang Yu-Yanran, Yang Zhuo-Jin, Hou Bei-Lin, Chen Jie, Yao Zhen, Liao Qi, Gao Fei-Fei, Zhang Yu-Xiang, Yan Chun-Xia
Аннотация
Opioid addiction involves maladaptive neuroplasticity within hippocampal circuits, yet the underlying molecular mechanisms remain incompletely understood. Here, we systematically investigated whether pyroptosis, a pro-inflammatory form of programmed cell death, contributes to morphine-induced neuroadaptations and reward memory formation. Using a combination of behavioral, molecular, pharmacological, and cellular approaches in a mouse model of conditioned place preference (CPP), we demonstrate that morphine exposure selectively activates GSDMD-mediated pyroptotic signaling in the dorsal hippocampus (dHip). Morphine-treated mice exhibited significantly elevated expression of pyroptosis-related proteins (GSDMD, GSDMD-N, Caspase-1, and IL-1β) specifically in the dHip, as well as enhanced immunofluorescence intensity within CA3 neuronal populations. Pharmacological inhibition of GSDMD pore formation with dimethyl fumarate (DMF) not only attenuated morphine-induced CPP but also reversed the upregulation of pyroptotic markers in dHip neurons. Complementary in vitro experiments in HT-22 hippocampal neuronal cells confirmed that morphine directly induces dose-dependent upregulation of pyroptosis-related genes and proteins, effects that were abrogated by DMF co-treatment. These findings identify neuronal pyroptosis as a previously unrecognized mechanism associated with morphine-associated reward memory and position GSDMD as a potential therapeutic target that warrants further investigation for mitigating opioid-induced maladaptive plasticity.